CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDED AND RESTATED LICENSE,...License, Development and Commercialization Agreement • May 1st, 2017 • Ignyta, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 1st, 2017 Company Industry JurisdictionThis Amended and Restated License, Development and Commercialization Agreement (this “Agreement”), dated as of March 22, 2017 (the “Effective Date”), is made by and between Eli Lilly and Company, an Indiana corporation (“Lilly”), and Ignyta, Inc., a Delaware corporation (“Licensee”). Lilly and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. LICENSE, DEVELOPMENT AND...License, Development and Commercialization Agreement • April 13th, 2016 • Ignyta, Inc. • Pharmaceutical preparations • New York
Contract Type FiledApril 13th, 2016 Company Industry JurisdictionThis License, Development and Commercialization Agreement (this “Agreement”), dated as of November 6, 2015 (the “Effective Date”), is made by and between Eli Lilly and Company, an Indiana corporation (“Lilly”), and Ignyta, Inc., a Delaware corporation (“Licensee”). Lilly and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. LICENSE, DEVELOPMENT AND...License, Development and Commercialization Agreement • December 23rd, 2015 • Ignyta, Inc. • Pharmaceutical preparations • New York
Contract Type FiledDecember 23rd, 2015 Company Industry JurisdictionThis License, Development and Commercialization Agreement (this “Agreement”), dated as of November 6, 2015 (the “Effective Date”), is made by and between Eli Lilly and Company, an Indiana corporation (“Lilly”), and Ignyta, Inc., a Delaware corporation (“Licensee”). Lilly and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.